Eikon Therapeutics, Inc. Common Stock (NASDAQ:EIKN) — Market Cap & Net Worth
Market Cap & Net Worth: Eikon Therapeutics, Inc. Common Stock (EIKN)
Eikon Therapeutics, Inc. Common Stock (NASDAQ:EIKN) has a market capitalization of $404.61 Million ($404.61 Million) as of October 11, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13445 globally and #3226 in its home market, demonstrating a 0.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eikon Therapeutics, Inc. Common Stock's stock price $7.47 by its total outstanding shares 54165030 (54.17 Million).
Eikon Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Eikon Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $404.61 Million to $404.61 Million (0.00% CAGR). Check Eikon Therapeutics, Inc. Common Stock share price for real-time trading data and today's change.
Eikon Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eikon Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see how efficiently does Eikon Therapeutics, Inc. Common Stock generate cash for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EIKN by Market Capitalization
Companies near Eikon Therapeutics, Inc. Common Stock in the global market cap rankings as of October 11, 2026. See Eikon Therapeutics, Inc. Common Stock balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Eikon Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Eikon Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Eikon Therapeutics, Inc. Common Stock's market cap moved from $404.61 Million to $ 404.61 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $404.61 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Eikon Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $404.61 Million USD |
| MoneyControl | $404.61 Million USD |
| MarketWatch | $404.61 Million USD |
| marketcap.company | $404.61 Million USD |
| Reuters | $404.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more